CD4 and leukemia: As anticipated, JAKi co-treatment suppressed in vivo CAR T cell activity with delayed leukemia clearance compared to TSLPRCART and vehicle treatment (Fig. 2G) and led to preferential decrement in CD4+ T cell numbers (Fig. 2H).